You are here

TMS as a Translational Tool to Bridge Pathophysiology to Novel Interventions in Autism Spectrum Disorder


Warning message

This Grand Rounds Webinar is restricted to registered participants or on-demand registrants. Click the following link to register: Register Here

Presenting: TMS as a Translational Tool to Bridge Pathophysiology to Novel Interventions in Autism Spectrum Disorder

You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series:

TMS as a Translational Tool to Bridge Pathophysiology to Novel Interventions in Autism Spectrum Disorder

Learning objectives: 

1.     Review the findings of studies using TMS to probe the mechanisms of intracortical inhibition and plasticity in autism spectrum disorder (ASD).

2.     Describe how TMS can be used to induce long-term changes in brain network functioning and potentially treat core and associated symptoms of ASD and related disorders.

3.     Identify a number of potential network targets where applying TMS may be effective for reducing specific targeted symptom domains.


Release Date: May 10, 2019

Date of Expiration: May 9, 2021

Format: On-Demand

Cost: Members: $25 | Non-members $50 | Student Members FREE

Speakers: Dr. Lindsay Oberman, PhD

Dr. Lindsay Oberman, PhD is the Clinical Program Leader for TMS trials at the Center for Neuroscience and Regenerative Medicine with a faculty appointment in the Department of Medical and Clinical Psychology at the Uniformed Services University (USU).  She is also a “Special Volunteer” in the Noninvasive Neuromodulation Unit, National Institute of Mental Health, National Institutes of Health.  The focus of her research is to investigate the mechanisms that contribute to the function and dysfunction of neural systems involved in the core symptoms of complex neuropsychiatric disorders with the ultimate goal of developing novel treatment strategies.  Over the past 16 years working in this field, she has gained an appreciation for the complexity of the pathophysiology of behaviorally defined disorders. Thus, she has recently shifted her focus to identifying and modifying neural circuits associated with specific cross diagnostic behavioral domains (such as mood regulation, sensory processing, social cognition, language processing, and executive functioning/cognitive control) in order to better target the symptoms that affect the quality of life of individuals with neuropsychiatric and neurodevelopmental disorders including autism spectrum disorder, traumatic brain injury, and post-traumatic stress disorder.


Vertical Tabs

Vertical Tabs

Acknowledgement of Commercial Support

No financial or in-kind commercial support was received for this educational activity.


Satisfactory completion
Learners must complete an evaluation to receive a certificate of completion. You must participate in the entire webinar; partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.




In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Clinical TMS Society. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­6.2, 6.5)


All individuals in a position to control the content of CE are listed below.


First Name

Last Name

Commercial Interest:Relationship



American Psychiatric Association Publishing:Other






Greenbrook TMS:Stock Shareholder











Questions? Email